10-Q: OraSure Reports Wider Losses Amid Revenue Decline, Strategic Shifts

OraSure Technologies, Inc. reported a significant increase in net loss and a substantial revenue decline for the three and nine months ended September 30, 2025, driven by reduced demand for COVID-19 tests and lower international HIV revenues, despite strategic acquisitions and cost-cutting measures.

Summary

• Net revenues decreased by 32% to $27.1 million for the three months ended September 30, 2025, compared to $39.9 million in the prior year period.
• Net revenues decreased by 41% to $88.3 million for the nine months ended September 30, 2025, compared to $148.4 million in the prior year period.
• The company reported a net loss of $13.7 million ($0.19 per share) for the three months ended September 30, 2025, a significant increase from a $4.5 million net loss ($0.06 per share) in the same period last year.
• For the nine months ended September 30, 2025, the net loss widened to $49.4 million ($0.67 per share) from $8.7 million ($0.12 per share) in the prior year period.
• Operating loss for the three months ended September 30, 2025, was $16.1 million, up from $6.0 million in the prior year, and for the nine months, it was $51.9 million, up from $15.8 million.
• Cash and cash equivalents decreased to $216.5 million at September 30, 2025, from $267.8 million at December 31, 2024.
• Net cash used in operating activities was $40.0 million for the nine months ended September 30, 2025, a shift from $27.3 million provided in the prior year.
• Research and development expenses increased by 80% to $10.1 million for the three months and 56% to $31.1 million for the nine months, primarily due to clinical trials for the Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) device and costs from the Sherlock acquisition.
• Sales of Diagnostics products decreased by 34% for the three months and 10% for the nine months, mainly due to lower international HIV revenues and reduced funding for domestic HIV programs.
• COVID-19 Diagnostics revenues plummeted by 96% for the three months and 99% for the nine months, reflecting decreased sales of InteliSwab tests and lower overall demand.
• The company discontinued its Risk Assessment product line and Molecular Services business, which contributed to revenue declines in those segments.
• Non-product and services revenues increased significantly due to funded R&D contracts assumed from the Sherlock acquisition and other BARDA contracts.
• A stock repurchase program authorized in March 2025 led to the repurchase of 3.3 million shares for $10.0 million during the nine months ended September 30, 2025.
• The company entered into a definitive merger agreement to acquire BioMedomics, Inc. for $4.0 million in cash plus contingent consideration, expected to close in Q4 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant declines in revenue and widening net losses, coupled with a shift to negative cash flow from operations. While strategic acquisitions and R&D investments are forward-looking, the current financial performance is a major concern. The ongoing litigation and risks associated with government funding and shutdowns further contribute to a cautious outlook.

Positives

• Gross profit margin slightly increased to 43.5% for the three months ended September 30, 2025, from 42.8% in the prior year, driven by an improved product mix of higher-margin sales and higher non-product revenues.
• Non-product and services revenues increased by 565% for the three months and 307% for the nine months, primarily due to new funded R&D contracts from the Sherlock acquisition and other BARDA contracts.
• Sales and marketing expenses decreased by 17% for the three months and 19% for the nine months, attributed to lower employee costs from workforce reductions.
• The launch of Syphilis revenue partially offset declines in other diagnostic product lines for the nine-month period.
• The company is strategically expanding its portfolio with the acquisition of Sherlock Biosciences (completed December 2024) and the planned acquisition of BioMedomics, Inc. (expected Q4 2025), aiming to offer a more comprehensive range of diagnostic tests.

Negatives

• Consolidated net revenues decreased significantly by 32% for the three months and 41% for the nine months ended September 30, 2025.
• Net loss widened substantially to $13.7 million for the three months and $49.4 million for the nine months ended September 30, 2025.
• Operating loss increased to $16.1 million for the three months and $51.9 million for the nine months ended September 30, 2025.
• Cash and cash equivalents decreased by $51.3 million from December 31, 2024, to September 30, 2025.
• Net cash used in operating activities was $40.0 million for the nine months ended September 30, 2025, a significant deterioration from cash provided in the prior year.
• Sales of Diagnostics products, particularly international HIV and domestic HIV (Together Take Me Home program), experienced declines due to reduced funding and changing customer ordering patterns.
• Sample Management Solutions revenues were negatively impacted by a large customer's bankruptcy proceedings.
• COVID-19 Diagnostics revenues saw a drastic 96-99% decrease due to decreased sales of InteliSwab tests and lower overall demand.
• The discontinuance of the Risk Assessment product line and Molecular Services business resulted in a complete cessation of revenues from these segments.
• General and administrative expenses increased due to higher legal fees related to the NowDx litigation and additional costs from the Sherlock acquisition.
• The company continues to maintain a full valuation allowance against its U.S. deferred tax asset, indicating a lack of sustained profitability.

Risks

• Market acceptance and ability to sell products and services, including through third parties, may not meet expectations.
• Distributors or other customers may fail to meet purchase forecasts, historic purchase levels, or minimum purchase requirements.
• Significant customer concentrations could pose a risk if a major customer reduces orders or faces financial difficulties (e.g., large customer bankruptcy impacting Sample Management Solutions).
• Ability to manufacture products in accordance with specifications, performance standards, and quality requirements is crucial.
• Obtaining necessary regulatory approvals for new products or new indications/applications for existing products, and complying with regulatory requirements, can be costly and time-consuming.
• Failure to effectively resolve warning letters, audit observations, or other findings from the FDA or other regulators could impact operations.
• Reliance on strategic partners for critical activities under collaborative arrangements introduces risks related to changes in relationships, disputes, or disagreements.
• Ability to meet increased demand for products, if it arises, could be challenging.
• The impact of replacing distributors on the company's business could be negative.
• Inventory levels at distributors and other customers could affect future sales.
• Ability to achieve financial and strategic objectives, including increasing revenues and expanding international sales, is uncertain.
• Competition from new or better technology, lower-cost products, and other competitors could negatively impact the business.
• Reduction or deferral of public funding available to customers, particularly for HIV programs, can significantly impact revenues.
• Changes in market acceptance of products based on performance or changes in testing guidelines/recommendations (e.g., CDC) pose risks.
• Ability to fund research and development and other products and operations is critical.
• Reliance on sole supply sources for critical products and components could lead to increased costs and substantial delays if vendors are unable or unwilling to supply.
• The impact of contracting with the U.S. government on the company's business, including procurement contracts, is a risk.
• Negative economic conditions, including interest rates, inflationary pressures, capital market disruptions, and recession, could impact the business.
• Ability to achieve and maintain sustained profitability and increase gross margins is uncertain.
• Uncertainty relating to patent protection and potential patent infringement claims, as well as the costs of litigation, are ongoing risks.
• Obstacles to international marketing and manufacturing of products, changes in international funding sources, and adverse movements in foreign currency exchange rates affect international sales.
• Loss or impairment of sources of capital could hinder operations.
• Ability to attract and retain qualified personnel is essential.
• Exposure to product liability and other types of litigation is a business risk.
• Changes in international, federal, or state laws and regulations could impact operations.
• Customer consolidations and inventory practices can affect sales.
• Equipment failures and ability to obtain needed raw materials and components are operational risks.
• The impact of terrorist attacks, civil unrest, hostilities, and war could disrupt business.
• The impact of cybersecurity incidents and other disruptions involving computer systems or third-party IT service providers, suppliers, and customers is a significant risk.
• General political, business, and economic conditions, including government shutdowns, can negatively impact business. Specifically, the U.S. government shutdown beginning October 1, 2025, and associated layoffs could hinder regulatory agencies (FDA, SEC) and government-funded programs, potentially delaying product development and approvals.

Future Outlook

The company expects COVID-19 diagnostics revenue to continue at current low levels throughout the remainder of 2025 and for the foreseeable future due to contract fulfillment and lower overall demand. The company is focused on expanding its portfolio with new diagnostic tests, such as the Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) device, with an FDA submission expected in late 2025 or early 2026. The acquisition of BioMedomics, Inc. is anticipated to close in the fourth quarter of 2025, further expanding product offerings. The company expects existing cash and cash equivalents to be sufficient to fund operating expenses and capital expenditure requirements over the next twelve months, but acknowledges potential variability due to strategic acquisitions, R&D programs, litigation, and market conditions.

Management Comments

• "The Company expects this level of revenue [COVID-19] to continue throughout the remainder of 2025 and for the foreseeable future due to the fulfillment of these contracts and lower overall demand for COVID-19 testing."
• "The Company continues to believe the full valuation allowance established against its total U.S. deferred tax asset is appropriate as the facts and circumstances necessitating the allowance have not changed."
• "Although the Company has achieved U.S. cumulative pre-tax earnings based on a rolling three year window the Company has not achieved a level of sustained profitability that would, in its judgment, support the release of the valuation allowance."

Industry Context

The diagnostics industry is experiencing a significant shift away from COVID-19 testing, impacting companies that had substantial revenue from pandemic-related products. OraSure's substantial decline in COVID-19 revenues aligns with this broader trend. The company's strategic acquisitions of Sherlock Biosciences and BioMedomics, along with its investment in Sapphiros, indicate a pivot towards expanding its portfolio in sexually transmitted infections (STIs) and low-cost diagnostic tests, which are areas of ongoing demand. The focus on clinical trials for new diagnostic devices like the CT/NG test reflects the competitive nature of the diagnostics market, requiring continuous innovation and regulatory navigation. The decline in international HIV funding also highlights the vulnerability of companies reliant on public health programs.

Corporate Governance

Legal Proceedings

• On November 14, 2024, the company filed a complaint against NowDiagnostics, Inc., Jody Berry, and Janean Young in the U.S. District Court for the Eastern District of Pennsylvania, alleging misappropriation of proprietary information and trade secrets, breach of contract, duty of loyalty, unfair competition, and tortious interference.
• NowDiagnostics filed counterclaims on January 13, 2025, and the company filed its answer on February 3, 2025.
• A motion to dismiss claims against Young was denied by the court on February 4, 2025.
• A preliminary injunction was agreed upon by NowDx, Berry, and Young, and entered by the Court on February 27, 2025.
• The case is currently in the discovery phase, with the schedule for further proceedings pending.

Stakeholder Impact

• Shareholders: Negative impact from significant net losses and declining stock price, partially offset by the ongoing stock repurchase program which could support share value.
• Employees: Impacted by workforce reductions in 2024, with some reductions still being completed in 2025. New acquisitions may create new opportunities.
• Customers: Discontinuation of Risk Assessment and Molecular Services lines may affect certain customer segments, while new products from Sherlock and BioMedomics aim to expand offerings.
• Suppliers: Risk of increased costs and delays due to reliance on sole-supply vendors for critical components.
• Creditors: The company's declining cash position and increased operating losses could be a concern, though current cash reserves are deemed sufficient for the next 12 months.

Next Steps

• Submit the Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) device to the FDA for regulatory approval in late 2025 or early 2026.
• Close the definitive merger agreement with BioMedomics, Inc. within the fourth quarter of 2025.
• Complete the Q2 2024 workforce reduction, including facility consolidation, by October 2025.
• Complete the Q3 2024 workforce reduction, related to the discontinuance of the risk assessment business, by December 2025.
• Continue to manage the ongoing litigation with NowDiagnostics, Inc., which is currently in the discovery phase.

Key Dates

Recommendation

The company's financial performance shows significant deterioration, with substantial declines in revenue and widening net losses for both the three and nine months ended September 30, 2025. The shift from positive to negative cash flow from operations is a major red flag, indicating increased cash burn. While strategic acquisitions like Sherlock Biosciences and BioMedomics aim to diversify the product portfolio and R&D spending is up for new products, these initiatives have not yet translated into improved financial results and are contributing to higher operating expenses. The discontinuance of multiple product lines, impact of a large customer's bankruptcy, and reduced demand for key products like COVID-19 tests highlight ongoing operational challenges. The company's inability to release its valuation allowance on deferred tax assets further underscores a lack of sustained profitability. Given the significant financial headwinds, increased losses, and negative cash flow, a seasoned investor would likely recommend selling the stock to mitigate further downside risk until there is clear evidence of a turnaround in core business performance and profitability.

Keywords

Diagnostics, HIV testing, HCV testing, Syphilis testing, COVID-19 testing, Sample Management Solutions, Molecular Diagnostics, SEC filing, 10-Q, Financial results, Net loss, Revenue decline, Operating expenses, Research and Development, Acquisition, BioMedomics, Sherlock Biosciences, Workforce reduction, Stock repurchase, Clinical trials, Regulatory approval, Government shutdown, Trade secrets litigation